Developmental cell death in dopaminergic neurons of the substantia nigra of mice.
Dopaminergic neurons in the substantia nigra pars compacta (SNpc) undergo natural cell death during development in rats. Controversy exists as to the occurrence of this phenomenon in SNpc dopaminergic neurons in the developing mouse. Herein, by using an array of morphologic techniques, we show that many SNpc neurons fulfill the criteria for apoptosis and that the number of apoptotic neurons in the SNpc vary in a time-dependent manner from postnatal day 2 to 32. These dying neurons also show evidence of DNA fragmentation, of activated caspase-3, and of cleavage of beta-actin. Some, but not all of the SNpc apoptotic neurons still express their phenotypic marker tyrosine hydroxylase, confirming their dopaminergic nature. Consistent with the importance of target-derived trophic support in modulating developmental cell death, we demonstrate that destruction of intrinsic striatal neurons by a local injection of quinolinic acid (QA) dramatically enhances the magnitude of SNpc apoptosis and results in a lower number of adult SNpc dopaminergic neurons. Strengthening the apoptotic nature of the observed SNpc developmental cell death, we demonstrate that overexpression of the anti-apoptotic protein Bcl-2 attenuates both natural and QA-induced SNpc apoptosis. The present study provides compelling evidence that developmental neuronal death with a morphology of apoptosis does occur in the SNpc of mice and that this process plays a critical role in regulating the adult number of dopaminergic neurons in the SNpc.
Jackson-Lewis
V
V
Neuroscience Research, Movement Disorder Division, Department of Neurology, Columbia University, New York, New York 10032, USA.
Vila
M
M
Djaldetti
R
R
Guegan
C
C
Liberatore
G
G
Liu
J
J
O'Malley
K L
KL
Burke
R E
RE
Przedborski
S
S
D000367:Age Factors; D000818:Animals; D000831:Animals, Newborn; D017209:Apoptosis / Q000502:physiology*; D051017:Apoptosis Regulatory Proteins; D002352:Carrier Proteins / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism*; D005260:Female; D018507:Gene Expression Regulation, Developmental / Q000502:physiology; D008297:Male; D051379:Mice / Q000033:anatomy & histology / Q000254:growth & development* / Q000378:metabolism; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D017072:Neostriatum / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology; D009410:Nerve Degeneration / Q000139:chemically induced; D009474:Neurons / Q000378:metabolism* / Q000648:ultrastructure; D010300:Parkinson Disease / Q000209:etiology / Q000503:physiopathology; D015398:Signal Transduction / Q000502:physiology; D013378:Substantia Nigra / Q000254:growth & development* / Q000378:metabolism / Q000648:ultrastructure; D013997:Time Factors
D051017:Apoptosis Regulatory Proteins; D002352:Carrier Proteins; C090468:TP53BP2 protein, human; D004298:Dopamine